Listed

Ernexa Therapeutics Inc.: Form 10-K for the period ended Dec 31, 2015

Filed with the SEC on Mar 15, 2016 and accepted by EDGAR at Mar 15, 2016, 13:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2015-01-01 to 2015-12-31$24.5mus-gaap:Revenues
Selling, general and administrative12 months2015-01-01 to 2015-12-31$18.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2015-01-01 to 2015-12-31−$6.9mus-gaap:OperatingIncomeLoss
Income tax12 months2015-01-01 to 2015-12-31$12.0kus-gaap:IncomeTaxExpenseBenefit
Net income12 months2015-01-01 to 2015-12-31−$7.2mus-gaap:NetIncomeLoss
Diluted EPS12 months2015-01-01 to 2015-12-31−$0.08us-gaap:EarningsPerShareBasicAndDiluted
Capital expenditure12 months2015-01-01 to 2015-12-31$991.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2015-12-31$3.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-12-31$9.1mus-gaap:AssetsCurrent
Total assetsAt period end2015-12-31$16.4mus-gaap:Assets
Current liabilitiesAt period end2015-12-31$5.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-12-31$12.6mus-gaap:Liabilities
Long-term debtAt period end2015-12-31$7.4mus-gaap:LongTermDebt
Current portion of debtAt period end2015-12-31$1.1mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2015-12-31$3.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-16-008049. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.